Modeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoids

Moshe J Willner1*, Yang Xiao1*, Hye Sung Kim1,2,3,4, Xuejing Chen1,5, Bin Xu6 and Kam W Leong1,7

Abstract
The COVID-19 pandemic has aggravated a preexisting epidemic: the opioid crisis. Much literature has shown that the circumstances imposed by COVID-19, such as social distancing regulations, medical and financial instability, and increased mental health issues, have been detrimental to those with opioid use disorder (OUD). In addition, unexpected neurological sequelae in COVID-19 patients suggest that COVID-19 compromises neuroimmunity, induces hypoxia, and causes respiratory depression, provoking similar effects as those caused by opioid exposure. Combined conditions of COVID-19 and OUD could lead to exacerbated complications. With limited human in vivo options to study these complications, we suggest that iPSC-derived brain organoid models may serve as a useful platform to investigate the physiological connection between COVID-19 and OUD. This mini-review highlights the advances of brain organoids in other neuropsychiatric and infectious diseases and suggests their potential utility for investigating OUD and COVID-19, respectively.

Keywords
COVID-19, SARS-CoV-2, opioid use disorder, neuropsychiatric disease, brain organoid

Introduction
The worldwide COVID-19 pandemic, caused by the SARS-CoV-2 virus, arrived in the midst of another epidemic: the opioid crisis. Opioid use disorder (OUD), a substance use and addictive disorder defined in part by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (5th edition; DSM-5) as the desire to take opioids despite social and professional consequences, currently affects 40.5 million people worldwide, but the opioid crisis was actually beginning to decline as more people were gaining access to effective treatment options.1–3 COVID-19 may reverse this trend, though, as people with OUD often experience significant challenges in healthcare that could be aggravated by the pandemic.1 For example, quarantine and social distancing measures could disrupt both vital social support groups and medication for addiction treatment, which is generally administered in person.4 Those with OUD could also be more likely to contract COVID-19 due to cognitive impairment, lower awareness of risk, and diminished efforts regarding personal protection in patients, further disrupting treatment.5,6 Such premature
treatment cessation dramatically increases overdose rates. In addition, the rise in fear, anxiety, and depression caused by COVID-19, induced by medical and financial instabilities, can be especially harmful to people with pre-existing mental health conditions and can cause relapses, worsening of these conditions, and increased substance usage.7,8 Indeed, since the rise of COVID-19, the United States has seen an increase of 32% for non-prescribed fentanyl and an 11% increase in drug overdose deaths in the first 4 months of 2020 as compared with those of last year.9

Although there is much discussion on the circumstantial ramifications of COVID-19, SARS-CoV-2 infection itself might prove to be directly challenging for those with OUD, who generally show worse overall health and increased susceptibility to infectious disease complications.10 COVID-19 is primarily known to induce sequelae such as respiratory distress syndromes and multiple organ dysfunction syndromes, but clinical observations indicated that patients with more severe cases also developed neurological and neuropsychiatric manifestations targeting the central nervous system (CNS), including dizziness, impaired consciousness, encephalitis, ataxia, acute cerebrovascular disease, and taste/smell impairment.11,12 Furthermore, long-term COVID-19-related psychiatric symptoms are still unknown; the significantly elevated prevalence of mental health issues in survivors of SARS-CoV, including posttraumatic stress disorder (PTSD), depression, and anxiety, took years to develop.13,14 These could further affect those with OUD who, in addition to addiction, typically suffer from comorbid psychopathologies such as depression, anxiety, and dizziness.15,16

Some of the neurological symptoms in the patients with COVID-19, such as encephalitis, may be caused by neuroimmunologic responses that stimulate inflammatory damage in the CNS.13 Similarly, opioids bind to various opioid receptors in the CNS to modulate the neuroimmune system, stimulating both high levels of pro-inflammatory and neurotoxic cytokines (IL-6, IL-1β, TNFα) and those that are anti-inflammatory and neuroprotective (IL-10, TGF-β, and BDNF).17,18 In addition, risks of opioid-related respiratory depression are likely amplified by COVID-19.19 SARS-CoV-2 infiltration in subcortical respiratory control centers could lead to observed hypoxia and respiratory distress.20 Opioids also target the brainstem to cause dysregulation of respiratory and cardiac functions, leading to damaging hypoxic consequences in the brain and other tissues.21 Moreover, the primary drugs prescribed for OUD treatment, methadone and buprenorphine, are partial opioid receptor agonists that could cause significant respiratory distress, the effects of which could be exacerbated by SARS-CoV-2 infection, unanticipated drug-drug interactions with novel COVID-19 therapeutics, and recently imposed self-administration of these highly potent treatments.19,22–24

The potential physiological connection between OUD and COVID-19 has been implicated in peripheral immune function as well. Opioid usage can have differential immune system responses, causing both immunosuppressive and immunostimulatory effects on cytokine secretion and chemokine receptor activation.10,25,26 SARS-CoV-2 demonstrates similar adverse effects on peripheral immune responses. It causes a lack in Interferon Type I/III (IFN-1/3) response while simultaneously inducing high levels of chemokines, suggesting COVID-19 severity is tied to a cytokine storm.27,28 These peripheral responses may also elicit neurological symptoms through precipitating neuroinflammatory responses or disrupting neurotransmission.13

Currently, our knowledge of how those with OUD may respond to COVID-19 is limited due to lack of research. However, based on the observations described above (Figure 1), we fear that sustaining COVID-19 and OUD could lead to especially serious complications and more complex interventions because of the effects that both have in compromising neuroimmunity and inducing hypoxia and respiratory distress. Our fears are not unfounded, as both COVID-19 and OUD patients with comorbidities have poorer prognoses and more severe cases.27,29–31

Animal models, important to study pathology, transmission, and host responses, have been used to investigate both SARS-CoV-2 infection22,33 and opioid addiction (Table 2). However, physiological differences among species provoked speculation that established animal models lack of good correlates for SARS-CoV-2. Indeed, animal models have historically led to a particular failure in neuropsychiatric drug development.34–37 An animal model to study both OUD and COVID-19, though significant, would still bear both sets of limitations. Because human in vivo investigation is difficult due to ethical considerations, the safety of handling patients with SARS-CoV-2, and the limitation in identifying patients who have had both OUD and COVID-19,35 human tissue-based models will provide critical validation steps to fill in our knowledge gap. A large portion of understanding both the individual and combined effects of OUD and COVID-19 on the brain will thus fall on these in vitro models that best mimic human physiology.38

Organoids, self-assembled three-dimensional (3D) aggregates generated from human induced pluripotent stem cells (iPSCs), most effectively recapitulate the cytoarchitecture and functional features of native tissues.39 Researchers have recognized organoids’ superior ability to mimic viral pathophysiology and investigate pharmacodynamics, and they have sprinted to develop in vitro organoid models to evaluate the response and drug candidates in COVID-19 cases.40

In this mini-review, we will briefly describe brain organoids and their advantages. We will then highlight the advances of brain organoids in neuropsychiatric and infectious diseases to understand their role in investigating OUD and COVID-19, respectively. Last, we will discuss their potential to study COVID-19 infection in those with OUD.
What are brain organoids?

Understanding the human brain, with both its vast number of specialized cell types and complex connectivity, has been historically challenging. Knowledge of the biological bases of neuropsychiatric disorders is unsatisfactory, too, and human health continues to suffer. This reality is primarily due to our limited access to the healthy human brain; most of our knowledge is built on human pathological or post-mortem specimens, animal studies, and in vitro 2D culture models. These models, although invaluable, are unable to capture the full scope of the living human brain, and they are limited by inherent species differences, concerns over tissue availability and manipulation, and lack of cell diversity and structural organization. Recent advances in cellular reprogramming and stem cell culture techniques have enabled the in vitro generation of 3D brain organoids from an individual’s unique genetic background.

Brain organoids are self-assembled 3D cellular aggregates that are generated from embryonic stem cells (ESCs) or iPSCs to mimic the brain. These brain organoids, which contain a 3D-organized heterogeneous cell population, can partially recapitulate some of the brain’s structure, developmental stages, and functionality, such as synapse formation and intercellular signal transmission.

In addition, brain organoids can model specific regions of the brain; a variety of protocols demonstrate the generation of brain organoids to model the development of cortex, hypothalamus, midbrain, and cerebellum. To generate brain organoids, iPSCs can be derived via the reprogramming of somatic cells. iPSCs can self-organize to form embryoid bodies (EBs). These EBs could then be cultured in the presence of neural induction molecules and region-specific patterning factors to give rise to brain organoids modeling specific brain regions (Figure 2).

Each protocol details a distinct cocktail of patterning molecules (e.g. SMAD inhibitor and WNT3A) and generates brain organoids with cellular heterogeneity and spatial architecture. For instance, cerebral organoids consist of upper-layer and deep-layer neurons, radial glia cells, and neural progenitors that display a rosette-like structure mimicking the subventricular-like zone.

In addition, brain organoids can be easily accessed for live imaging of temporal and spatial changes, drug responses, electrophysiological activities, and high throughput transcriptomic and proteomic profiling.

Figure 1. Illustration summarizing the circumstantial complications (right, patient) and SARS-CoV-2 infection complications (left, physician) that the COVID-19 pandemic can potentially have on those with OUD.
The mechanics of certain mutations or disorders can then be understood by comparing control organoids to those bearing specific genetic modifications or originating from patients. With these strategies, in addition to the advantages provided by a 3D platform, brain organoids hold promise as relevant and powerful tools to model human brain development and disease.

Brain organoid models for OUD and neuropsychiatric diseases

OUD is part of the wide range of neuropsychiatric disorders in which neurodevelopmental features and neurological functions have been comprised.62–64 OUD and other substance use disorders are usually compounded with additional neuropsychiatric disorders, such as depression, anxiety, schizophrenia, bipolar disorder, attention-deficit hyperactivity disorder (ADHD), psychotic illness, borderline personality disorder, and antisocial personality disorder.65–68 Researchers have posed several reasons for such a high prevalence of comorbidity between OUD and other neuropsychiatric disorders: (1) they target similar brain regions (nucleus accumbens, ventral tegmental area, prefrontal cortex, hippocampus, amygdala) and neural circuitry (implicating the reward system, decision making, impulse control, stress response, and emotions); (2) they share common molecular mechanisms affected by various genetic, epigenetic, and environmental factors such as genetic mutations, stress, adversity, trauma, and drug exposure; and/or access; (3) there are numerous clinical similarities and overlapping symptoms with each other, and one disease may unmask or exacerbate the symptoms of the other.67 However, the precise mechanisms for many neuropsychiatric diseases, including OUD, are unclear, and further investigation is crucial for a greater understanding of the nature of these diseases and their complex relationship.

Although OUD has yet to be investigated using brain organoids, many studies have been conducted on other neuropsychiatric diseases. These studies successfully investigated similar pathways and regions that would be relevant to OUD, suggesting that brain organoids can provide a viable framework for studying human brain disorders and explore potential therapeutics. To show the power of brain organoids for OUD, we will first highlight several significant advances that brain organoids have made in a few kinds of neuropsychiatric disorders: neurodevelopmental, psychotic, mood, and neurodegenerative.

Figure 2. Schematic representation of general brain organoid generation. Human iPSCs self-assemble into embryoid bodies, and then sequentially undergo induction, differentiation, and maturation to form brain organoids. These organoids can mimic specific brain regions and model corresponding functional studies. Neurobiological mechanisms of various brain disorders can be investigated using patient-derived or genetically mutated iPSCs, as well as with the appropriate brain region.
the known imbalances in excitatory and inhibitory neurotransmission found in Down Syndrome were shown to be recovered by shRNA-mediated knockdown of OLIG2 in patient-derived forebrain organoids.87,88

**Psychotic disorders**

Schizophrenia is characterized by many symptoms, including delusions, hallucinations, amotivation, anhedonia, and cognitive deficits, that are thought to arise from disrupted neurodevelopment.89,90 Patient-derived organoids confirmed the hypothesized impaired telencephalic neuronal development, attributing it to reduced FGFR1 expression, and also demonstrated aberrant immune response, mitochondrial function, increased TNFα and decreased Wnt signaling, and excitatory/inhibitory neurotransmission.91–95

In addition, mutations in DISC1(disrupted-in-schizophrenia 1) have been established as a genetic risk factor for various psychiatric disorders including schizophrenia, but the mechanism of how DISC1 disrupts brain function is not well known.96,97 Cerebral organoids suggested that disturbing the interaction between DISC1 and Ndel1/Nde1 impairs cell-cycle progression during mitosis.98 Organoids also revealed that the smaller rosette structures, elevated WNT signaling, disorganized layer specificity, and dysregulated cell fate could be rescued by correcting the DISC1 mutation or using a WNT antagonist.99,100

**Mood disorder**

Previous investigation into bipolar disorder (BD), a psychiatric disorder that is characterized by recurring episodes of depression and mania, have implicated certain genes and impairments in BD patients.101–105 Forebrain organoids corroborated these findings and also exposed dysregulated nervous system development, differentiation, immune signaling, and electrical stimulation.

**Neurodegenerative disorders**

Alzheimer’s disease (AD), associated with severe age-related memory impairments, is a neurodegenerative disorder characterized by amyloid plaques, neurofibrillary tangles, and tau pathology (tauopathy).106 Raja et al. first demonstrated that these AD pathologies could be replicated in patient-derived organoids, and treatment of these organoids with β- and γ-secretase inhibitors, known AD therapeutics, significantly reduced amyloid and taupathy.107 CRISPR/Cas9-altered organoids showed that organoids with apolipoprotein E4 (APOE4), a known risk factor in AD, recapitulated multiple AD phenotypes.108,109 More investigations revealed further mechanisms.110–117

Many other neurodegenerative disorders have been investigated with brain organoids, too. Midbrain organoids successfully recapitulated the abnormal differentiation and increased cell death of dopaminergic neurons reminiscent of Parkinson’s disease (PD).118,119 A later study also identified that the LRRK2 G2019S gene mutation associated with PD causes α-synuclein accumulation, mitochondrial dysfunction, increased neurotoxicity, and impaired dopamine signaling.120 In addition, cerebral organoids confirmed the role of p25/Cdk5 in human taupathy, characteristic of frontotemporal dementia.121 Last, it has been suggested that Huntington’s disease, an inherited neurodegenerative disease caused by an expansion of CAG repeats in the huntingtin gene, is caused by earlier abnormal development.122,123 Huntington’s disease patient-derived cerebral organoids modeled this irregular neural development, demonstrating failure of neuroectodermal acquisition, abnormal neural rosette formation, disrupted cell organization, impaired cortical fate differentiation, and terminal neuronal maturation.124 Molecular and pharmacological approaches targeting the huntingtin mutation restored striatal normalcy, suggesting that an early intervention may revert neurodegeneration later in life.

The above studies, summarized in Table 1, demonstrate the viability of using brain organoids to interrogate the disease biology for a wide range of neuropsychiatric disorders. Although OUD itself has yet to be investigated with brain organoids, the approaches described in these studies provide a roadmap for future interrogation of OUD.

Molecular mechanisms of opioid exposure on the brain were revealed by transcriptome profiling and its downstream annotation analysis (Table 2). RNA sequencing (RNA-seq), along with downstream Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, help find affected biological processes and pathways. These experiments have revealed common signaling pathways and biological processes shared between OUD and these related neuropsychiatric disorders. Brain organoids would provide a more nuanced understanding of these processes particular to OUD, including specific gene targets, morphological abnormalities, and therapeutic possibilities.

An example of a mutual biological process would be the dysregulated immune functioning and inflammation found in several neuropsychiatric disorder organoid studies, which is partially due to impaired IFNγ, NF-κB, and other signaling pathways.86,93,102,109 Karagiannis et al. similarly found that acute and chronic opioid exposure impairs the antiviral gene program through genes related to IFN cell signaling,174 while others have shown that deviant pro- and anti-inflammatory cytokine generation is due to aberrant toll-like receptor (TLR) and NF-κB signaling.153,155,188 It has further been observed that heroin-dependent patients (HDPs) exhibit lessened cytokine secretion due to the downregulation of TNFα signaling pathways.151,189,190

In addition, brain organoid studies have revealed imbalanced excitatory/inhibitory neurotransmission,72,73,88,93 which could further elucidate how chronic opioid exposure increases glutamatergic signaling.152,154 Furthermore, HDPs shared commonly upregulated genes with those who have PTSD, AD, PD, and HD, including those related
| Disease (Neuropsychiatric and Infectious) | Region-specific brain organoid used | Key findings | Reference(s) |
|------------------------------------------|-----------------------------------|--------------|--------------|
| Autism spectrum disorder                 | Telencephalic                      | Increased mature inhibitory neurons | Mariani et al.,72 Schafer et al.,73 Amiri et al.,77 Zhang et al.,78 Wang et al.79 |
|                                          | Cerebral                          | Abnormal cellular differentiation | |
|                                          | Forebrain                         | Neurodevelopmental temporal dysregulation | |
|                                          |                                   | Enhanced synaptic development | |
|                                          |                                   | Alterations rescued by FOXG1, CHD8-KO, RAB39b-KO | |
|                                          |                                   | Enriched PI3K-AKT-mTOR signaling | |
|                                          |                                   | Enlarged organoids | |
| Rett syndrome                            | Cerebral                          | Altered neurogenesis and neural differentiation | Mellios et al.,83 Xiang et al.84 |
| 16p13.11 Microduplication                | Cerebral                          | Reduced NPC proliferation, rescued by targeting NFκB p65 pathway | Johnstone et al.86 |
| Down syndrome                            | Forebrain                         | Increased OLIG2+ ventral forebrain neural progenitors | Xu et al.88 |
|                                          |                                   | Increased inhibitory interneurons | |
|                                          |                                   | Altered neurodevelopment | |
| Schizophrenia                            | Cerebral                          | Disrupted cellular organization and cell migration | Stachowiak et al.,91 Kathuria et al.,93 Benson et al.,94 Sawada et al.95 |
|                                          |                                   | Impaired neurodevelopment | |
|                                          |                                   | Several disrupted signaling pathways, including TNFα and Wnt | |
|                                          |                                   | Transfection of FGFR1 rescued abnormalities | |
|                                          |                                   | Dysregulated genes related to ECM | |
| DISC1 mutation                           | Forebrain                         | Mutation disrupted DISC1-Ndel1/Nde1 interaction | Ye et al.,98 Srikanth et al.,99 Qian et al.100 |
|                                          | Cerebral                          | Delayed cell-cycle progression | |
|                                          | Cortical                          | Smaller rosettes, disorganized cell layers | |
|                                          |                                   | Alterations rescued by WNT antagonist | |
| Bipolar disorder                         | Cerebral (patterned after dorsal forebrain) | Impaired cell adhesion, neurodevelopment, synaptic biology, and immune signaling | Kathuria et al.102 |
|                                          |                                   | Abnormal response to electrical stimulation | |
| Alzheimer’s disease                      | Cerebral                          | Amyloid aggregation, hyperphosphorylated tau protein, endosome abnormalities | Lambert et al.,108 Lin et al.,109 Pavoni et al.,110 Gonzalez et al.,111 Meyer et al.,112 Arber et al.,113 Ghatak et al.,114 Perez et al.,115 Yan et al.,116 Zhao et al.,117 |
|                                          | Neuroectodermal                   | Altered synaptic function, lipid metabolism, immune and inflammatory responses, neural differentiation, electrical activity, ECM composition, mitochondrial unfolding and clearance | |
|                                          | Forebrain                         | Increased apoptosis and cell death | |
|                                          |                                   | APOE4 recapitulated AD phenotypes | |
|                                          |                                   | β- and γ-secretase inhibitors, DAPT, heparin, and heparinase reduced pathology | |

(Continued)
| Disease (Neuropsychiatric and Infectious) | Region-specific brain organoid used | Key findings                                                                                                                                                                                                 | Reference(s)                                                                 |
|--------------------------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Parkinson’s disease                  | Midbrain                          | Altered development of midbrain dopaminergic neurons                                                                                                                                                    | Smits et al.,118 Kwak et al.,119 Kim et al.,120                                  |
|                                      |                                   | Increased apoptosis, α-synuclein inclusions, FOXA2 expression G2019S mutation in LRRK2 recapitulated PD phenotypes                                      |                                                                               |
| Frontotemporal dementia              | Cerebral                          | Reduced levels of phosphorylated tau and increased expression of synaptophysin upon blocking p25 generation                                                                                        | Seo et al.,121                                                                 |
| Huntington’s disease                 | Cerebral                          | Disrupted cytoarchitecture, neural development                                                                                                                                                    | Conforti et al.,124                                                             |
|                                      | Cortical                          | Alterations rescued by downregulation of mutant HTT                                                                                                                                            |                                                                               |
| Zika virus                           | Cortical                          | Disrupted neurogenesis, neurodevelopment                                                                                                                                                    | Qian et al.,51 Cugola et al.,125 Garcez et al.,126 Dang et al.,127 Watanabe et al.,128 Ayala-Nunez et al.,129 Gabriel et al.,130 Li et al.,131 Sacramento et al.,132 Setoh et al.,133 Wells et al.,134 Xu et al.,135,136 Yoon et al.,137 Zhang et al.,138 Zhou et al.,139 Janssens et al.,140 Nowakowski et al.,141 Li et al.,142 |
|                                      | Cerebral                          | Increased cell death, decreased organoid size and cortical folding                                                                                                                                     |                                                                               |
|                                      | Forebrain                         | Several potential viral entry receptors and therapeutics were found and tested to prevent infection                                                                                                     |                                                                               |
| La crosse virus                      | Cerebral                          | Increased apoptosis                                                                                                                                                                                   | Winkler et al.,143                                                             |
| Japanese Encephalitis virus          | Telencephalon                     | Viability rescued by recombinant Type 1 IFN                                                                                                                                                           | Zhang et al.,144                                                               |
| Human Cytomegalovirus                | Forebrain                         | Infected astrocytes and outer radial glial cells                                                                                                                                                      | Sison et al.,145 Guoqiang et al.,146 Brown et al.,147                           |
|                                      | Cerebral                          | Increased cell death, decreased cell proliferation                                                                                                                                                    |                                                                               |
| Herpes simplex virus-1              | Cerebral                          | Abnormal neurodevelopment and neural layering                                                                                                                                                        | Qiao et al.,148                                                                |
|                                      |                                  | Decreased organoid size                                                                                                                                                                                 |                                                                               |
|                                      |                                  | Dysregulated calcium                                                                                                                                                                                   |                                                                               |
| Sporadic Creutzfeldt-Jakob disease   | Cerebral                          | Impaired neural differentiation, cortical layering, brain regionalization Abnormal microglial proliferation and activation Increased inflammatory factors TNFβ, IL-4, IL-6, IL-10 | Groveman et al.,149                                                           |
| Toxoplasma Gondii                    | Cerebral                          | Increased metabolism, LDH release, and cytokine release                                                                                                                                               | Seo et al.,150                                                                |

Neuropsychiatric diseases are in bold, and infectious diseases are in italics.
Table 2. Affected biological processes and pathways by opioids and corresponding literature support.

| Category                  | GO/KEGG term                                 | Species   | Drug                        | Effects                                                                 |
|---------------------------|----------------------------------------------|-----------|-----------------------------|-------------------------------------------------------------------------|
| Neural function           |                                              |           |                             |                                                                         |
| Alzheimer’s disease       |                                              | Human     | Heroin\(^{151}\)            | White matter degeneration in the brain\(^{152}\)                       |
| Amphetamine addiction     |                                              | Mouse     | Morphine\(^{153}\)          | Nociceptive sensitization, hyperalgesia\(^{154}\)                      |
| Calcium signaling pathway |                                              | Mouse     | Morphine\(^{155}\)          | Analgesia\(^{156,157}\)                                               |
| Cell projection morphogenesis |                                            | Mouse     | Morphine\(^{155}\)          | Structural plasticity\(^{158}\)                                       |
| Cell morphogenesis involved in neuron differentiation | | Mouse   | Heroin\(^{155}\) | Neural plasticity\(^{159}\) |
| Ensheathment of neurons   |                                              | Mouse     | Morphine\(^{155}\)          | Synaptic plasticity, fast impulse conduction\(^{160-162}\)            |
| Glutamatergic synapse     |                                              | Mouse     | Morphine\(^{153}\)          | Nociceptive sensitization, hyperalgesia\(^{154}\)                      |
| Huntington’s disease      |                                              | Human     | Morphine, Heroin\(^{151,163}\) | Synaptic plasticity\(^{160}\)                                        |
| Long-term potentiation    |                                              | Mouse     | Morphine\(^{153,163}\)      | Tolerance, dependence\(^{164}\)                                       |
| Nicotine addiction        |                                              | Mouse     | Morphine\(^{153}\)          | Nociceptive sensitization, hyperalgesia\(^{154}\)                      |
| Parkinson’s disease       |                                              | Human     | Heroin\(^{151}\)            | Increased apoptosis\(^{120}\)                                         |
| Potassium ion transport   |                                              | Mouse     | Heroin\(^{155}\)            | Proanalgesic effect\(^{156}\)                                        |
| Regulation of circadian rhythm |                                            | Mouse     | Morphine\(^{153}\)          | Modulated pain sensation\(^{153,165}\)                                |
| Regulation of excitatory postsynaptic membrane potential | | Mouse | Heroin\(^{155}\) | Tolerance, hyperalgesia\(^{156}\) |
| Regulation of nervous system development | | Mouse | Heroin\(^{155}\) | Neural plasticity, tolerance, dependence\(^{166}\) |
| Regulation of neuron death |                                            | Mouse     | Heroin\(^{155}\)            | Anti-inflammatory effect, analgesia\(^{166-168}\)                     |
| Regulation of programmed cell death | | Mouse | Morphine\(^{155}\) | Production of pro-inflammatory cytokines, tolerance, hyperalgesia\(^{154,169}\) |
| Regulation of synapse organization | | Mouse | Heroin\(^{155}\) | Analgesia, autophagy\(^{154,170}\) |
| Synaptic transmission, GABAergic | | Mouse | Morphine\(^{155}\) | Pro-inflammatory responses, tolerance, affective control\(^{169,171,172}\) |
| Synaptic transmission, glutamatergic | | Mouse | Morphine\(^{155}\) | Analgesia, conditioned place preference memory acquisition\(^{156,173}\) |
| Voltage-gated ion channel activity | | Mouse | Morphine\(^{153}\) | Nociceptive sensitization, hyperalgesia\(^{154}\) |
| Defense response to virus |                                              | Human     | Heroin\(^{151}\)            | Adverse effect in immune system\(^{151,174}\)                         |
| Humoral immune response   |                                              | Mouse     | Morphine\(^{155}\)          | Anti-inflammatory effect, analgesia\(^{175,176}\)                     |
| Immune response           |                                              | Mouse     | Oxycodeone\(^{177}\)        | Pro-inflammatory responses\(^{177}\)                                  |
| Inflammatory response     |                                              | Mouse     | Oxycodeone\(^{177}\)        | Anti-inflammatory effect, analgesia\(^{175,176}\)                     |
| Innate immune response    |                                              | Human     | Heroin, Morphine\(^{155,151}\) | Pro-inflammatory responses, tolerance\(^{156,169,178}\)               |
| MAPK signaling pathway    |                                              | Mouse     | Morphine\(^{155}\)          | Pro-inflammatory responses, analgesia, hyperalgesia, analgesic tolerance\(^{179-181}\) |
| Negative regulation of NF-κB TF activity | | Mouse | Morphine\(^{155}\) | Analgesia, NF-κB activation\(^{169}\) |
| Response to xenobiotic stimulus | | Mouse | Morphine\(^{155}\) | Tolerance\(^{175,182}\) |
| TNF signaling pathway     |                                              | Human     | Heroin\(^{51}\)             | Impaired hematopoiesis and circulation\(^{151}\)                      |
| Toll-like receptor signaling pathway | | Mouse | Morphine\(^{155,153}\) | Allodynia, hyperalgesia, NF-κB activation\(^{190,183-187}\) |
to oxidative phosphorylation and metabolic pathways (ATP5D, ATP5H, HSD17B10/NDUFB11, NDUFBA8, NDUFB7). Opioid exposure additionally caused dysregulated programmed cell death, synapse organization, cell morphogenesis, brain volume, and neuron differentiation, similar to several of the above brain organoid studies.

Although these animal models and human postmortem opioid studies are revealing, these experiments were designed to study specific functions and are limited in investigating the effects of opioids. Brain organoids provide unique access to human tissue that could be manipulated and assessed in order to expound on these effects of opioid exposure and inform on more precise mechanisms. Synthesizing the above opioid and brain organoid studies would be helpful to conduct further research on OUD.

To begin this further investigation, we tested the response to opioid exposure of niche cells in midbrain organoids, which were generated using previously described protocols. Our preliminary analyses suggested that brain organoids are a powerful model for recapitulating both human brain development and drug response. First, chronic opioid usage arrested the development of neural progenitors, delaying the formation and maturation of the neuroblasts and neurons. This is comparable to the previous mouse studies that showed the inhibition of embryonic neurogenesis in the developing cortex due to morphine exposure, and a rebound increase in radial glial cell and neural progenitor proliferation and differentiation resulted from drug withdrawal. Second, opioid exposure downregulated inflammatory responses, which is in line with its role in neuroinflammatory responses in both peripheral and central nervous systems. Third, opioids led to alterations in neurotransmission and neural activity, which is consistent with their regulation of neurotransmitters through opioid receptors and downstream cAMP signaling pathways.

Interestingly, our results suggested that opioid exposure effects organoids in a cell-type specific manner as well. For instance, compared to untreated midbrain organoids, genes associated with synapse assembly and ion transport were more frequently altered in opioid-treated oculomotor and trochlear nucleus (OMTN) neurons, while genes associated with neuron development were less frequently altered in opioid-treated radial glia cells. These findings suggest that brain organoids are viable models for OUD and could further identify OUD-specific neuronal pathways and biological processes, as well as screen for potential drug candidates.

This section has reviewed the literature demonstrating that brain organoids are viable models to investigate some key aspects of OUD and neuropsychiatric diseases. In addition, our group’s current project using midbrain organoids to study OUD has been encouraging. However, there is still much more to learn using these models, such as genetic variants prone to addiction, precise neuropathological mechanisms, and drug-drug interactions, in order to better understand both OUD and these complex diseases.

**Brain organoid models for COVID-19 and infectious diseases**

Although COVID-19 has presented neurological symptoms, and SARS-CoV-2 has been detected in patients’ cerebrospinal fluid (CSF), the precise mechanisms of neurological infection and its complications are largely unclear. The low expression of angiotensin-converting enzyme 2 (ACE2), a protein crucial for SARS-CoV-2 viral entry, in the CNS has evoked considerations that there are other mechanisms of action for neurological invasion. Suggested mechanisms include retrograde neuronal transport, exosomal cellular transport, hematogenous routes, immune injury, and hypoxia damage. Further studies, however, are required to determine both neuropathogenesis and neurotropism.

Brain organoids have successfully been used to study several infectious diseases and their effects on the human brain, giving hope for brain organoids to do the same for COVID-19.

The prime example for this is Zika virus (ZIKV), a virus that is associated with microcephaly and congenital brain malformations; during the global health emergency starting in 2015, brain organoids were essential to help determine its neuropathogenesis. ZIKV successfully infected brain organoids, which additionally demonstrated that it causes microcephalic phenotypes such as cell death and reduced organoid growth. Brain organoids were then used to suggest viral entry receptors that potentially cause microcephaly. Many successive studies have since used transcriptomics and morphology to investigate ZIKV molecular pathways, neurotropism, and potential therapeutics. A recent study even found that ZIKV alters DNA methylation and could potentially cause delayed-onset neuropsychiatric complications.

Other infectious viruses have been studied with brain organoids, too. La Crosse Virus (LACV) is an arthropod-borne orthobunyavirus that causes many symptoms such as pediatric arboviral encephalitis, learning and memory deficits, and seizures. Cerebral organoids inoculated with LACV showed increased apoptosis, where committed neurons underwent apoptosis at a higher rate than neural progenitors. The susceptibility to infection was found to be due to poor IFN-1 response in less mature neurons, and exogenous administration of IFN-1 induction rescued this cell viability. Japanese encephalitis (JE) virus, a disease caused by the Japanese encephalitis virus (JEV) with no effective cure for infected patients, causes bleeding and inflammatory infiltration in multiple brain regions, as well as longer-term neurological sequelae. Telencephalon organoids found that JEV preferentially infects astrocytes and outer radial glial cells, stunts cell proliferation, and induces cell death. Human Cytomegalovirus (HCMV) infection modulates intracellular calcium signaling and can result in infants born with a variety of symptoms, including hepatosplenomegaly, microcephaly, and developmental disabilities.
Organoids revealed the mechanisms altering calcium signaling and also demonstrated disrupted cortical neural layering, terminal differentiation, cell viability, and organoid growth.143–147 These studies also determined potential cellular receptors relevant to HCMV infection, and demonstrated that certain viral inhibitors and neutralizing antibodies could restore normal structural features. Neonatal herpes simplex virus type 1 (HSV-1), a member of the herpesviridae family, can cause various neurodevelopmental disabilities and necrotizing encephalitis that last well into adulthood.148

Brain organoids have even been exploited to investigate non-virus pathogens. Sporadic Creutzfeldt-Jakob Disease (sCJD), a transmissible neurodegenerative disease targeting several brain regions and caused by infectious prions, was shown with cerebral organoids to increase metabolism, LDH release, and cytokine release.149,215,216 Toxoplasmosa gondii (TG), an intracellular protozoan parasite with no vaccine or effective treatment, can cause several CNS diseases and neurodevelopmental defects such as mental retardation, seizures, and microcephaly.150,217,218 The unusual asexual life cycle of TG, which alternates between tissue cyst-forming bradyzoites and inflammation-inducing tachyzoites, requires a heterogeneous cell population for replication that has had underwhelming results in 2D cultures.150,218–220 Cerebral organoids were able to stimulate the complex TG asexual life cycle, including parasitophorous vacuoles that form cysts, and revealed that TG preferentially infects neuronal cells, astrocytes, and oligodendrocytes and primarily evokes an immune response from IFN-1.150

These studies have established brain organoids as a viable experimental infectious model, as summarized in Table 1. Because of this potential to also study SARS-CoV-2 CNS viral entry, which requires ACE2 expression, researchers are sprinting to develop in vitro organoid models to evaluate tropism and drug candidates in COVID-19 cases of tissues at risk (i.e., those that express ACE2).198,199,221,222 Since it has been shown that both brain tissue and brain organoids express ACE2, brain organoids have recently been identified to study the neurotropism and neuropathogenesis of COVID-19, too. Very little is known with regards to SARS-CoV-2 neurotropism, but early results from several brain organoid studies have since provided some information.225–231

Although all studies have demonstrated that brain organoids were susceptible to SARS-CoV-2 infection, reports vary as to which specific cell types were indeed infected. One study reported that only cortical neurons were infected as opposed to neural progenitors, suggesting that SARS-CoV-2 prefers more mature neuronal cell types (Figure 3(a)).225 Other studies, however, observed that SARS-CoV-2 infected other cell types, too, including neural progenitors, radial glia, dopaminergic neurons, and astrocytes.226–230 Upon observing that choroid plexus (CP) epithelial cells had a much higher tropism than neurons in cortical organoids, two studies developed CP organoids and demonstrated a heightened SARS-CoV-2 viral spike protein expression in CP epithelial cells (Figure 3(b)).227,231 All together, these studies suggest that there is some degree of neurotropism in COVID-19.

These studies also investigated the connection between cell-specific tropism and ACE2 expression. RNA sequencing demonstrated that only small amounts of ACE2 were found in neurons, neural progenitors, and astrocytes, with much higher expression found in CP epithelial cells and especially in the CP organoids.225–228,230,231 However, immunofluorescence staining showed a more widespread expression of ACE2, indicating that ACE2 may be expressed on the cell surface and that mRNA levels were not necessarily the best representation of ACE2 amount (Figure 3(d)).226 Although some studies found an overlap between SARS-CoV-2 positive cells and ACE2 expression,227,231 others found no correlation between the two.226,228 In addition, some studies found that there was a time-dependent increase in SARS-CoV-2-positive cells, indicating that the virus was able to replicate in brain organoids (Figure 3(a)) whereas other studies found that the virus could not productively replicate.225,227

Regions with robust infection were also found to have syncytia, caused by cell-cell fusion through the interaction between SARS-CoV-2 spike protein and ACE2 expressed on adjacent cells.227,229 Song et al. also found that SARS-CoV-2 infection was inhibited by ACE2 antibodies (Figure 3(d)).226 These results indicate that although ACE2 might be a critical cell entry receptor for CNS infection, it is likely that there are also other routes of infection that need to be further investigated. For example, cell-cell fusion was reported with SARS-CoV-2 infection of several cell types and was a major mechanism by which the virus spreads to adjacent cells.232–234

Brain organoids also revealed significant neurotoxicity caused by SARS-CoV-2 infection. TUNEL and cleaved caspase 3 immunolabeling demonstrated that SARS-CoV-2 infection causes significant cell death as compared with control organoids (Figure 3(c)).225–227,229,230 Some observed this cell death even in uninfected cells adjacent to infected cells, suggesting that infected cells may induce adjacent cells to die through an extrinsic mechanism.226,227 Several different mechanisms could have contributed to the observed neurotoxicity. SARS-CoV-2 impaired synaptogenesis and induced a locally hypoxic environment in neuronal regions, which aids in lowering the threshold for tissue damage.226,230 In addition, cell-cell junctions of the epithelial cell layer of the choroid plexus, an integral part of the blood-CNS barrier that prevents the entry of pathogens, immune cells, and cytokines into the CSF and brain, were visibly damaged.231,235,236 Such barrier breakdown...
could allow abnormal entry of immune cells and cytokines, leading to harmful neuroinflammation.

Furthermore, brain organoids were found to display tau missorting, where tau is mislocalized in the somatodendritic region rather than on the axons of mature neurons, and tau hyperphosphorylation. Taupathy is reminiscent of AD and other neurodegenerative diseases, suggesting that perhaps COVID-19 can cause chronic or long-term damage in the CNS.

Single-cell RNA sequencing, along with gene ontology analyses, further revealed the neuropathogenesis of SARS-CoV-2, identifying dysregulated cell division, inflammatory responses, cellular function, and metabolic processes (Figure 3(e)). In addition, pathways in both infected and uninfected cells were enriched, but in different ways, and dysregulated gene expression varies widely among various tissue organoids infected with SARS-CoV-2. This suggests unique responses in different cell types and highlights the need for diverse cellular model systems when studying the disease.

A few different therapies to inhibit SARS-CoV-2 infection were tested, too. Sofosbuvir, an FDA-approved anti-hepatitis C treatment that suppresses viral families of single-stranded, positive-sense RNA viruses such as coronaviruses, successfully decreased the amount of neuronal cell death, viral accumulation, and synaptic damage. In addition, SARS-CoV-2 infection was inhibited by both anti-ACE2 antibodies and CSF-containing antiviral antibodies. Overall, brain organoids have provided a lot of information about SARS-CoV-2 neurotropism, and these models are established as a viable method to continue further and necessary investigation.

Summary and perspectives

As outlined in the introduction, there are a lot of potential complications between OUD and COVID-19. Both present neurological and psychiatric manifestations, cause respiratory depression, immune system dysfunction, and hypoxia, and are both aggravated by comorbidities.
Brain organoid studies investigating OUD and COVID-19, as well as related neuropsychiatric disorders and infectious diseases, have revealed further potential complications. Our preliminary study of OUD using midbrain organoids demonstrated that opioid exposure impairs neuronal differentiation and activity, as well as induces hypoxic and alters immune functioning in the CNS. It has been shown that SARS-CoV-2 infection, too, impairs neuronal viability and differentiation, while also stimulating a hypoxic and inflammatory CNS environment. In addition, the synaptic damage and tau pathologies associated with SARS-CoV-2 are reminiscent of similar findings in neurodevelopmental and neurodegenerative disorders, arousing concern that COVID-19 could cause long-term CNS damage.

It would thus be prudent to investigate COVID-19 complications in individuals with OUD through brain organoids, which could be accomplished using one of the following approaches: (1) generate organoids with OUD patient-derived iPSCs, and subsequently inoculate them with SARS-CoV-2; (2) generate organoids with COVID-19 patient-derived iPSCs, and subsequently expose them to opioids and recapitulate the effects of OUD; (3) generate organoids from control iPSCs and both inoculate them with SARS-CoV-2 and expose them to opioids. If the first, ideal option cannot be accomplished, the second and third options can also provide fundamental mechanistic insights.

Brain organoids can be used to investigate both the individual and combined effects of OUD and COVID-19 on the brain. Each model can be characterized and validated using similar tactics to the ones we exemplified (Figure 4). For instance, high-throughput proteomic and transcriptomic profiling could identify affected neuronal pathways and biological processes on a single cell level, revealing the particular difficulties COVID-19 contributes to those with OUD. Additional cell-type specific SARS-CoV-2 viral entry could also be tracked to develop novel COVID-19 drug candidates. Brain organoids hold potential to screen these candidates both individually and in conjunction with OUD therapeutics, such as methadone and buprenorphine.240 Histological analysis could further demonstrate the effects of these diseases on morphology, architecture, electrophysiological function, and cellular
heterogeneity. We suggest that brain organoids would reveal how COVID-19 leads to worsened phenotypes and more complicated interventions in those with OUD.

Although brain organoids are extremely helpful, limitations do exist, such as incomplete cell maturation and heterogeneity, brain tissue architecture, transcriptional networks, and vasculature.34,47,48,241 With the rapid evolution of brain organoid technology, we expect that broader aspects of COVID-19 complications can be investigated. For example, using improved brain organoid generation protocols that promote the yield of microglia, astrocytes, and endothelial cells with ACE2 expression, more accurate viral pathology and mechanisms of infection could be investigated.225,241,242 In addition, since brain organoids more closely resemble the developing fetal brain than the mature adult brain, there may exist important differences in SARS-CoV-2 susceptibility between immature and mature brains.227 Organoids with better maturity and cell and tissue type diversity are paramount to a better understanding of the interactions between COVID-19 and OUD, along with the development of more efficacious interventions.

Challenges in understanding the complications of COVID-19 is huge and urgent, especially to monitor long-term CNS consequences.228 It will need interdisciplinary efforts from both clinical and basic studies. Hopefully, brain organoid and other established modeling can provide complementary information to improve our understanding and treatment of OUD in the wake of other viral infections and complications.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Support by the National Institutes of Health (UH3TR002151) is acknowledged.

ORCID iD
Kam W Leong https://orcid.org/0000-0002-8133-4955

References
1. Sun Y, Bao Y, Kosten T, et al. Editorial: challenges to opioid use disorders during COVID-19. Am J Addict 2020; 29: 174–175.
2. Alexander GC, Stoller KB, Haffajee RL, et al. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med 2020; 173: 57–58.
3. Dydyk AM, Jain NK and Gupta M. Opioid use disorder. Treasure Island, FL: StatPearls, 2020.
4. Becker WC and Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med 2020; 173: 59–60.
5. Pfefferbaum B and North CS. Mental health and the Covid-19 pandemic. N Engl J Med 2020; 383: 510–512.
6. Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med 2020; 173: 61–62.
7. Yao H, Chen JH and Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry 2020; 7: e21.
8. Czeisler ME, Lane RI, Petrosky E, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic – United States, June 24–30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1049–1057.
9. Weiner S. COVID-19 and the Opioid Crisis: When a Pandemic and an Epidemic Collide. Association of American Medical Colleges. www.aamc.org/newsinsights/covid-19-and-opioid-crisis-when-pandemic-and-epidemic-collide (2020, accessed 23 September 2020).
10. Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol 2011; 6: 442–465.
11. Qi J, Zhou Y, Hua J, et al. The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to COVID-19 infection. bioRxiv 2020. DOI: 10.1101/2020.04.16.045690.
12. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683–690.
13. Troyer EA, Kohn JN and Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun 2020; 87: 34–39.
14. Lam MH, Wing YK, Yu MW, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med 2009; 169: 2142–2147.
15. Baldini A, Von Korff M and Lin EH. A review of potential adverse effects of long-term Opioid therapy: a practitioner’s guide. Prim Care Companion CNS Disord 2012; 14(3):PCC.11m01326.
16. De Nadai AS, Little TB, McCabe SE, et al. Diverse diagnostic profiles associated with prescription opioid use disorder in a nationwide sample: one crisis, multiple needs. J Consult Clin Psychol 2019; 87: 849–858.
17. Hofford RS, Russo SJ and Kiraly DD. Neuroimmune mechanisms of psychostimulant and opioid use disorders. Eur J Neurosci 2019; 50: 2562–2573.
18. Lacagnina MJ, Rivera PD and Bilbo SD. Glial and neuroimmune mechanisms as critical modulators of drug use and abuse. Neuropsychopharmacology 2017; 42: 156–177.
19. Schimmel J and Manini AF. Opioid use disorder and COVID-19: biological plausibility for worsened outcomes. Subst Use Misuse 2020; 55: 1900–1901.
20. Hartung HP and Aktas O. COVID-19 and management of neuroimmunological disorders. Nat Rev Neurol 2020; 16(7): 347–348.
21. van der Schier R, Roozekrans M, van Velzen M, et al. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep 2014; 6: 79.
22. Boyer J. COVID-19, medication-assisted treatment, and increased risk for further respiratory depression. Am J Psychiatry 2020; 177: 636.

23. Ferrari A, Coccia CP, Bertolini A, et al. Methadone—metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50: 551–559.

24. Elkader A and Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44: 661–680.

25. Saad MH, Rumschlag M, Guerra MH, et al. Differentially expressed gene networks, biomarkers, long noncoding RNAs, and shared responses with cocaine identified in the midbrains of human opioid abusers. Sci Rep 2019; 9: 1534.

26. Liang X, Liu R, Chen C, et al. Opioid system modulates the immune function: a review. Transl Perioper Pain Med 2016; 1: 5–13.

27. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020; 181(5): 1036–1045.e9.

28. Fu Y, Cheng Y and Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: From mechanisms to potential therapeutic tools. Virol Sin 2020; 35: 266–271.

29. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55: 2000547.

30. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91–95.

31. Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020; 12: 6049–6057.

32. Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol 2020; 21: 1327–1335.

33. Munoz-Fontela C, Dowling WE, Funnell SGP, et al. Animal models for COVID-19. Nature 2020; 586: 509–515.

34. Quadrato G, Brown J and Arlotta P. The promises and challenges of human brain organoids as models of neuropsychiatric disorders. Cell Stem Cell 2020; 8: 1144–1154.

35. Monzel AS, Smits LM, Hemmer K, et al. Derivation of human midbrain-specific organoids from neuroepithelial human pluripotent stem cells in 3D culture. Cell Rep 2020; 30: 1682–1689.e3.

36. Amin ND and Pasca SP. Building models of brain disorders with three-dimensional organoids. Neuron 2018; 100: 389–405.

37. Pankevich DE, Altevogt BM, Dunlop J, et al. Improving clinical testing of vaccines for SARS-CoV-2 and therapeutic agents. Proc Natl Acad Sci USA 2015; 112: 15672–15677.

38. Quadrato G, Nguyen T, Macosko EZ, et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nature 2017; 545: 48–53.

39. La Manno G, Gyllborg D, Codeluppi S, et al. Molecular diversity of midbrain development in mouse, human, and stem cells. Cell 2016; 167: 566–580 e519.

40. Thiry L, Hamel R, Pluchino S, et al. Characterization of human iPS-C derived spinal motor neurons by single-cell RNA sequencing. Neuroscience 2020; 450: 57–70.

41. Amin ND and Pasca SP. Building models of brain disorders with three-dimensional organoids. Neuron 2018; 100: 389–405.

42. Insel TR and Landis SC. Twenty-five years of progress: the view from NIMH and NINDS. Neuron 2013; 80: 561–567.
62. Peedicayil J. Identification of biomarkers in neuropsychiatric disorders based on systems biology and epigenetics. *Front Genet* 2019; 10: 985.
63. Scarnati MS, Halikere A and Pang ZP. Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: current status and outlook. *Alcohol* 2019; 74: 83–93.
64. Taber KH, Hurley RA and Yudofsky SC. Diagnosis and treatment of neuropsychiatric disorders. *Annu Rev Med* 2010; 61: 121–133.
65. Sharma B, Bruner A, Barnett G, et al. Opioid use disorders. *Child Adolesc Psychiatr Clin N Am* 2016; 25: 473–487.
66. National Institute on Drug Abuse. Common comorbidities with substance use disorders research report. National Institute on Drug Abuse. https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/why-where-comorbidity-between-substance-use-disorders-mental-illnesses (2020, accessed 14 June 2020).
67. Hartwell KJ, Tolliver BK and Brady KT. Biologic commonalities between mental illness and addiction. *Prim Psychiatry* 2009; 16: 33–39.
68. Ross S and Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. *Clin Neuropsycharmacol* 2012; 35: 235–243.
69. Montalvo-Ortiz JL, Cheng Z, Kranzler HR, et al. Genomewide study of epigenetic biomarkers of opioid dependence in European-American women. *Sci Rep* 2019; 9: 4660.
70. Lin CC and Huang T.L. Epigenetic biomarkers in neuropsychiatric disorders. *Neuropsychiatr Disord Epigenet* 2016: 35–66.
71. Moussas G, Christodoulou C and Douzenis A. A short review on the aetiology and pathophysiology of alcoholism. *Ann Gen Psychiatry* 2009; 8: 10.
72. Mariani J, Coppola G, Zhang P, et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. *Cell* 2015; 162: 375–390.
73. Schafer ST, Paquola ACM, Stern S, et al. Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. *Nat Neurosci* 2019; 22: 243–255.
74. Courchesne E, Mouton PR, Calhoun ME, et al. Neuron number and size in prefrontal cortex of children with autism. *JAMA* 2011; 306: 2001–2010.
75. Hutsler JJ and Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. *Brain Res* 2010; 1309: 83–94.
76. Rubenstein JL. Three hypotheses for developmental defects that may underlie some forms of autism spectrum disorder. *Curr Opin Neurol* 2010; 23: 118–123.
77. Amiri A, Coppola G, Scuderi S, et al. Transcriptome and epigenome landscape of human cortical development modeled in organoids. *Science* 2018; 362(6420): eaat6720.
78. Zhang W, Ma L, Yang M, et al. Cerebral organoid and mouse models reveal a RAB39B-Pi3K-mTOR pathway-dependent dysregulation of cortical development leading to macrocephaly/autism phenotypes. *Genes Dev* 2020; 34: 580–597.
79. Wang P, Mokhtari R, Pedrosa E, et al. CRISPR/Cas9-mediated heterozygous knockout of the autism gene CHD8 and characterization of its transcriptional networks in cerebral organoids derived from iPSC cells. *Mol Autism* 2017; 8: 11.
80. Bernier R, Golzio C, Xiong B, et al. Disruptive CHD8 mutations define a subtype of autism early in development. *Cell* 2014; 158: 263–276.
81. Giannandrea M, Bianchi V, Mignogna ML, et al. Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly. *Am J Hum Genet* 2010; 86: 185–195.
82. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999; 23: 185–188.
83. Mellios N, Feldman DA, Sheridan SD, et al. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling. *Mol Psychiatry* 2018; 23: 1051–1065.
84. Xiang Y, Tanaka Y, Patterson B, et al. Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons. *Mol Cell* 2020; 79: 84–98.e89.
85. Ullmann R, Turner G, Kirchhoff M, et al. Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. *Hum Mutat* 2007; 28: 674–682.
86. Johnston M, Vasistha NA, Barbuc MC, et al. Reversal of proliferation deficits caused by chromosome 16p13.11 microduplication through targeting NFkappaB signaling: an integrated study of patient-derived neuronal precursor cells, cerebral organoids and in vivo brain imaging. *Mol Psychiatry* 2019; 24: 294–311.
87. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. *Nat Neurosci* 2007; 10: 411–413.
88. Xu R, Brawner AT, Li S, et al. OLIG2 drives abnormal neurodevelopmental phenotypes in human iPSC-based organoid and chimeric mouse models of down syndrome. *Cell Stem Cell* 2019; 24: 908–926.e908.
89. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. *Lancet* 1995; 346: 477–481.
90. Stachowiak MK, Kucinski A, Curl R, et al. Schizophrenia: a neurodevelopmental disorder—integrative genomic hypothesis and therapeutic implications from a transgenic mouse model. *Schizophr Res* 2013; 143: 367–376.
91. Stachowiak EK, Benson CA, Narla ST, et al. Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1. *Transl Psychiatry* 2017; 7: 6.
92. Narla ST, Lee YW, Benson CA, et al. Common developmental genome deprogramming in schizophrenia—Role of Integrative Nuclear FGFR1 Signaling (INFS). *Schizophr Res* 2017; 185: 17–32.
93. Kathuria A, Lopez-Lengowski K, Jagtap SS, et al. Transcriptomic landscape and functional characterization of induced pluripotent stem cell-derived cerebral organoids in Schizophrenia. *JAMA Psychiatry* 2020; 77: 745–754.
94. Benson CA, Powell HR, Liput M, et al. Immune factor, TNFalpha, disrupts human brain organoid development similar to schizophrenia-schizophrenia increases developmental vulnerability to TNFalpha. Front Cell Neurosci 2020; 14: 233.

95. Sawada T, Chater TE, Sasagawa Y, et al. Developmental excitation-inhibition imbalance underlying psychoses revealed by single-cell analyses of discordant twins-derived cerebral organoids. Mol Psychiatry 2020; 25: 2695–2711.

96. Blackwood DH, Fordyce A, Walker MT, et al. Schizophrenia and affective disorders—co-segregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001; 69: 428–433.

97. Thomson PA, Malavasi EL, Grunewald E, et al. DISC1 genetics, biology and psychiatric illness. Front Biol (Beijing) 2013; 8: 1–31.

98. Ye F, Kang E, Yu C, et al. DISC1 Regulates Neurogenesis via modulating kinetochore attachment of Nde1/Nde1 during Mitosis. Neuron 2017; 96: 1041–1054 e1045.

99. Srikanth P, Lagomarsino VN, Muratore CR, et al. Shared effects of DISC1 disruption and elevated WNT signaling in human cerebral organoids. Transl Psychiatry 2018; 8: 77.

100. Qian X, Su Y, Adam CD, et al. Sliced human cortical organoids for modeling distinct cortical layer formation. Cell Stem Cell 2020; 26: 766–781.e769.

101. Granden I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet 2016; 387: 1561–1572.

102. Kathuria A, Lopez-Lengowski K, Vater M, et al. Transcriptome analysis and functional characterization of cerebral organoids in bipolar disorder. Genome Med 2020; 12: 34.

103. Craddock N and Sklar P. Genetics of bipolar disorder. Mol Psychiatry 2013; 18: 910–928.

104. Miller ND and Kelsoe JR. Unraveling the biology of bipolar disorder using induced pluripotent stem-derived neurons. Bipolar Disord 2017; 19: 544–551.

105. Stahl EA, Breen G, Forstner AJ, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet 2019; 51: 793–803.

106. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013; 80: 1778–1783.

107. Raja WK, Mungenast AE, Lin YT, et al. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulates alzheimer’s disease phenotypes. PLoS One 2016; 11: e0161969.

108. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013; 45: 1452–1458.

109. Lin YT, Seo J, Gao F, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron 2018; 98: 1141–1154 e1147.

110. Pavoni S, Jarray R, Nassor F, et al. Small-molecule induction of Abeta-42 peptide production in human cerebral organoids to model Alzheimer’s disease associated phenotypes. PLoS One 2018; 13: e0209150.

111. Gonzalez C, Armijo E, Bravo-Alegria J, et al. Modeling amyloid beta and tau pathology in human cerebral organoids. Mol Psychiatry 2018; 23: 2363–2374.

112. Meyer K, Feldman HM, Lu T, et al. REST and Neural gene network dysregulation in iPSC models of Alzheimer’s disease. Cell Rep 2019; 26: 1112–1127.e1119.

113. Arber C, Toombs J, Lovejoy C, et al. Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol Psychiatry 2020; 25: 2919–2931.

114. Ghatak S, Dolatabadi N, Trudler D, et al. Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. Elife 2019; 8.

115. Perez MJ, Ivanyuk D, Panagiotakopoulou V, et al. Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer’s disease-like pathology in human cerebral organoids. Mol Psychiatry. Epub ahead of print 7 July 2020. DOI: 10.1038/s41380-020-0807-4.

116. Yan Y, Song L, Bejoy J, et al. Modeling neurodegenerative microenvironment using cortical organoids derived from human stem cells. Tissue Eng Part A 2018; 24: 1125–1137.

117. Zhao J, Fu Y, Yamazaki Y, et al. APOE4 exacerbates synaptic loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoids. Nat Commun 2020; 11: 5540.

118. Smits LM, Reinhardt L, Reinhardt P, et al. Modeling Parkinson’s disease in midbrain-like organoids. NPJ Parkinsons Dis 2019; 5: 5.

119. Kwak TH, Kang JH, Hali S, et al. Generation of homogeneous midbrain organoids with in vivo-like cellular composition facilitates neurotoxin-based Parkinson’s disease modeling. Stem Cells 2020; 38: 727–740.

120. Kim H, Park HJ, Choi H, et al. Modeling G2019S-LRRK2 sporadic Parkinson’s disease in 3D midbrain organoids. Stem Cell Rep 2019; 12: 518–531.

121. Conforti P, Besussu D, Bocchi VD, et al. Faulty neuronal microenvironment using cortical organoids derived from human stem cells. Cell Stem Cell 2019; 26: 1112–1127.e1119.

122. HD iPSC Consortium. Developmental alterations in Huntington’s disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 2017; 20: 648–660.

123. Wiatr K, Szlachcic WJ, Trzeciak M, et al. Huntington disease as a neurodevelopmental Disorder and early signs of the disease in stem cells. Mol Neurobiol 2018; 55: 3351–3371.

124. Conforti P, Besussu D, Bocchi VD, et al. Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes. Proc Natl Acad Sci USA 2018; 115: E762–E771.

125. Cugola FR, Fernandes IR, Russo FB, et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 2016; 534: 267–271.

126. Garcez PP, Loiola EC, Madeiro da Costa R, et al. Zika virus impairs growth in human neurospheres and brain organoids. Science 2016; 352: 816–818.

127. Dang J, Tovar RK, Lichinchi G, et al. Zika Virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. Cell Stem Cell 2016; 19: 258–265.

128. Watanabe M, Buth JE, Vishalagi N, et al. Self-organized cerebral organoids with human-specific features predict effective drugs to combat Zika virus infection. Cell Rep 2017; 21: 517–532.

129. Ayala-Nunez NV, Follain G, Delalande F, et al. Zika virus enhances monocyte adhesion and transmigration...
favors viral dissemination to neural cells. Nat Commun 2019; 10: 4430.

130. Gabriel E, Ramani A, Karrow U, et al. Recent Zika Virus isolates induce premature differentiation of neural progenitors in human brain organoids. Cell Stem Cell 2017; 20: 397–406 e395.

131. Li C, Deng YQ, Wang S, et al. 25-Hydroxycholesterol protects host against Zika virus infection and its associated microcephaly in a mouse model. Immunity 2017; 46: 446–456.

132. Sacramento CQ, de Melo GR, de Freitas CS, et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 2017; 7: 40920.

133. Setoh YX, Amarilla AA, Peng NYG, et al. Determinants of Zika virus host tropism uncovered by deep mutational scanning. Nat Microbiol 2019; 4: 876–887.

134. Wells MF, Salick MR, Wiskow O, et al. Genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from Zika virus infection. Cell Stem Cell 2016; 19: 703–708.

135. Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 2016; 22: 1101–1107.

136. Xu YP, Qiu Y, Zhang B, et al. Zika virus infection induces RNAi-mediated antiviral immunity in human neural progenitors and brain organoids. Cell Res 2019; 29: 265–273.

137. Yoon KJ, Song G, Qian X, et al. Zika-virus-encoded NS2A disrupts mammalian cortical neurogenesis by degrading adherens junction proteins. Cell Stem Cell 2017; 21: 349–358 e346.

138. Zhang F, Hammack C, Ogden SC, et al. Molecular signatures associated with ZIKV exposure in human cortical progenitors. Nucleic Acids Res 2016; 44: 8610–8620.

139. Zhou T, Tan L, Cederquist GY, et al. High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brain. Cell Stem Cell 2017; 21: 274–283.e275.

140. Janssens S, Schotsmaert M, Karnik R, et al. Zika virus alters DNA methylation of neural genes in an organoid model of the developing human brain. mSystems 2018; 3.

141. Nowakowski TJ, Pollen AA, Di Lullo E, et al. Expression analysis highlights AXL as a candidate Zika virus entry receptor in Neural Stem Cells. Cell Stem Cell 2016; 18: 591–596.

142. Li Y, Muffat J, Omer A, et al. Induction of expansion and folding in human cerebral Organoids. Cell Stem Cell 2017; 20: 385–396 e383.

143. Winkler CW, Woods TA, Groveman BR, et al. Neuronal maturation reduces the type I IFN response to orthobunyavirus infection and leads to increased apoptosis of human neurons. J Neuroinflammation 2019; 16: 229.

144. Zhang B, He Y, Xu Y, et al. Differential antiviral immunity to Japanese encephalitis virus in developing cortical organoids. Cell Death Dis 2018; 9: 719.

145. Sison SL, O’Brien BS, Johnson AJ, et al. Human cytomegalovirus disruption of calcium signaling in neural progenitor cells and organoids. J Virol 2019; 93.

146. Sun G, Chiuppesi F, Chen X, et al. Modeling Human cytomegalovirus-induced microcephaly in human iPSC-derived brain organoids. Cell Rep Med 2020; 1: 1–15.

147. Brown RM, Rana P, Jaeger HK, et al. Human cytomegalovirus compromises development of cerebral organoids. J Virol 2019; 93.

148. Qiao H, Guo M, Shang J, et al. Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changes. PLoS Pathog 2020; 16: e1008899.

149. Groveman BR, Foliaki ST, Orru CD, et al. Sporadic Creutzfeldt-Jakob disease prion infection of human cerebral organoids. Acta Neuropathol Commun 2019; 7: 90.

150. Seo HH, Han HW, Lee SE, et al. Modelling Toxoplasma gondii infection in human cerebral organoids. Emerg Microbes Infect 2020; 9: 1943–1954.

151. Zhu M, Xu Y, Wang H, et al. Heroin abuse results in shifted RNA expression to neurodegenerative diseases and attenuation of TNFα signaling pathway. Sci Rep 2018; 8: 9231.

152. Li W, Li Q, Zhu J, et al. White matter impairment in chronic heroin dependence: a quantitative DTI study. Brain Res 2013; 1531: 58–64.

153. Zhang P, Moye LS, Southey BR, et al. Opioid-induced hyperalgesia is associated with dysregulation of circadian rhythm and adaptive immune pathways in the mouse trigeminal ganglia and nucleus accumbens. Molr Neurobiol 2019; 56: 7929–7949.

154. Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14: 145–161.

155. Wu X, Xie S, Wang L, et al. A computational strategy for finding novel targets and therapeutic compounds for opioid dependence. PLOS ONE 2018; 13: e0207027.

156. Parsadaniantz SM, Rivat C, Rostène W, et al. Opioid and chemokine receptor crosstalk: a promising target for pain therapy? Nat Rev Neurosci 2015; 16: 69–78.

157. Gudin J and Fudin J. A Narrative Pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther 2020; 9: 41–54.

158. Guegan T, Cebrià JP, Maldonado R, et al. Morphine-induced locomotor sensitization produces structural plasticity in the mesocorticolimbic system dependent on CB1-R activity. Addict Biol 2016; 21: 1113–1126.

159. Jia M, Wang X, Zhang H, et al. MicroRNA-132 in the adult dentate gyrus is involved in opioid addiction via modifying the differentiation of neural stem cells. Neurosci Bull 2019; 35: 486–496.

160. Silva-Rodrigues JF, Patricio-Rodrigues CF, de Sousa-Xavier V, et al. Peripheral axonal enervation is regulated by RaLA GTPase and the eoxcyst complex. Development 2020; 147: dev174540.

161. Banerjee S and Bhat MA. Glial enervation of peripheral axons in Drosophila. J Neurosci Res 2008; 86: 1189–1198.

162. Klockars A, Levine AS and Olszewski PK. Hypothalamic integration of the endocrine Signaling related to food intake. In: Coolen LM and Grattan DR (eds) Neuroendocrine regulation of behavior. Cham: Springer International Publishing, 2019, pp.239–269.

163. Tapocik JD, Letwin N, Mayo CL, et al. Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine. J Neurosci 2009; 29: 5295–5307.
164. Pu L, Bao G-B, Xu N-J, et al. Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. *J Neurosci* 2002; 22: 1914–1921.

165. Li S-x, Liu L-j, Jiang W-g, et al. Circadian alteration in neurobiology during protracted opiate withdrawal in rats. *J Neurochem* 2010; 115: 353–362.

166. Hauser KF and Knapp PE. Opiate drugs with abuse liability hijack the endogenous opioid system to disrupt neuronal and glial maturation in the central nervous system. *Front Pediatr* 2018; 5: 294.

167. Hong J, Cho I-H, Il Kwak K, et al. Microglial toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death. *J Biol Chemistry* 2010; 285: 39447–39457.

168. Mao J, Sung B, Ji R-R, et al. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. *J Neurosci* 2002; 22: 7650–7661.

169. Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. *Pharmacol Rev* 2011; 63: 772.

170. Georgoussi Z-I, Karoussiotis C, Sotiriou A, et al. The role of κ-opioid receptor-induced autophagy in synaptic alterations. *FASEB J* 2020; 34: 1–1.

171. Li Y, Li C-Y, Xi W, et al. Rostral and caudal ventral tegmental area GABAergic inputs to different dorsal Raphe neurons participate in opioid dependence. *Neuron* 2019; 101: 748–761.e745.

172. Stellwagen D, Beattie EC, Seo JY, et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. *Neuron* 2005; 45: 397–407.

173. Nam M-H, Han K-S, Lee J, et al. Activation of astrocytic μ-opioid receptor causes conditioned place preference. *J Neurosci* 2005; 25: 3219.

174. Ndengele MM, Cuzzocrea S, Masini E, et al. Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitrooxidative stress and neuroimmune activation. *J Pharmacol Exp Ther* 2009; 329: 64.

175. Lacagnina MJ, Watkins LR and Grace PM. Toll-like receptors and their role in persistent pain. *Pharmacol Ther* 2018; 184: 145–158.

176. Hutson LW, Lebonville CL, Jones ME, et al. Interleukin-1 signaling in the basolateral amygdala is necessary for heroin-conditioned immunosuppression. *Brain Behav Immun* 2017; 62: 171–179.

177. Mazzei M, D’Alessio FA, Klotz J, et al. Maternal cocaine exposure slows G2/M phase transition in radial glial and basal progenitor cells in the dorsal telencephalon of the E15.5 embryonic mouse. *Eur J Neurosci* 2008; 28: 1060–1067.

178. Kohn L, Alonso G, Normand E, et al. Repeated morphine treatment alters polysialylated neural cell adhesion molecule, glutamate decarboxylase-67 expression and cell proliferation in the adult rat hippocampus. *Eur J Neurosci* 2005; 21: 493–500.

179. Zhang P, Yang M, Chen C, et al. Toll-like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility. *Front Immunol* 2020; 11: 1455–1455.

180. Peng Y, Zhang M, Chen C, et al. Toll-like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility. *Front Immunol* 2020; 11: 1455–1455.

181. Deng M, Chen S-R, Chen H, et al. Mitogen-activated protein kinase signaling mediates opioid-induced presynaptic NMDA receptor activation and analgesic tolerance. *J Neurochem* 2019; 148: 275–290.

182. Perry VH, Hume DA and Gordon S. Immunohistochemical localization of macrophages and microglia in the adult and developing mouse brain. *Neuroscience* 1985; 15: 313–326.

183. Tanga FY, Raghavendra V and DeLeo JA. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. *Neurochem Int* 2004; 45: 397–407.

184. Tanga FY, Nutile-McMenemy N and DeLeo JA. The CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy. *Proc Natl Acad Sci USA* 2005; 102: 5856.

185. Hong J, Cho I-H, Il Kwak K, et al. Microglial toll-like receptor 2 contributes to kainic acid-induced glial activation and hippocampal neuronal cell death. *J Biol Chemistry* 2010; 285: 39447–39457.
196. Kreek MJ. Molecular and cellular neurobiology and pathophysiology of opiate addiction. In: Davis KL (ed) *Neuropsychopharmacology: the fifth generation of progress*. Philadelphia: Lippincott Williams & Wilkins, R., 2002, pp.1491–1506.

197. Xiang P, Xu XM, Gao LL, et al. First case of 2019 novel coronavirus disease with Encephalitis. *ChinaXiv* T202003.00015, 2020.

198. Toljan K. Letter to the editor regarding the viewpoint ‘Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanism’. *ACS Chem Neurosci* 2020; 11: 1192–1194.

199. Brann DH, Tsukahara T, Weinreb C, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. *Sci Adv* 2020; 6.

200. Wu Y, Xu X, Chen Z, et al. Nervous system involvement in COVID-19 in neurology and neurosurgery: a scoping review of the early literature. *Clin Neurol Neurosurg* 2020; 193: 105866.

201. Wilson MP and Jack AS. Coronavirus disease 2019 (COVID-19) in neurology and neuropsychiatry: a scoping review of the early literature. *Clin Neurol Neurosurg* 2020; 193: 105866.

202. Yesilkaya UH and Balcioglu YH. Neuroimmune correlates of the nervous system involvement of COVID-19: a commentary. *J Clin Neurol* 2020; 78: 449–450.

203. Holmes EA, O’Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *Lancet Psychiatry* 2020; 7: 547–560.

204. Driggers RW, Ho CY, Korhonen EM, et al. Zika Virus infection with prolonged maternal viremia and fetal brain abnormalities. *N Engl J Med* 2016; 374: 2142–2151.

205. Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. *N Engl J Med* 2016; 374: 951–958.

206. Heymann DL, Hodgson A, Sall AA, et al. Zika virus and microcephaly: why is this situation a PHEIC? *Lancet* 2016; 387: 719–721.

207. Haddow AD, Bixler D and Odoi A. The spatial epidemiology and clinical features of reported cases of La Crosse virus infection in West Virginia from 2003 to 2007. *BMC Infect Dis* 2011; 11: 29.

208. McLunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. *Pediatrics* 1997; 99: 261–267.

209. Mackenzie JS, Gubler DJ and Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. *Nat Med* 2004; 10: S98–S109.

210. Solomon T. Control of Japanese encephalitis—within our grasp? *N Engl J Med* 2006; 355: 869–871.

211. Pass RF and Arav-Boger R. Maternal and fetal cytomegalovirus infection: diagnosis, management, and prevention. *F1000Res* 2018; 7: 255.

212. Nokta M, Eaton D, Steinsland OS, et al. Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin. *Virology* 1987; 157: 259–267.

213. Mahic M, Mjaaland S, Bovelstad HM, et al. Maternal immunoreactivity to herpes simplex Virus 2 and risk of autism spectrum disorder in male offspring. *mSphere* 2017; 2.

214. Pinninti SG and Kimberlin DW. Preventing herpes simplex virus in the newborn. *Clin Perinatol* 2014; 41: 945–955.

215. Collinge J. Variant Creutzfeldt-Jakob disease. *Lancet* 1999; 354: 317–323.

216. Sikorska B, Knight R, Ironside JW, et al. Creutzfeldt-Jakob disease. *Adv Exp Med Biol* 2012; 724: 76–90.

217. Montazeri M, Sharif M, Sarvi S, et al. A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006-2016). *Front Microbiol* 2017; 8: 25.

218. Robert-Gangneux F and Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev* 2012; 25: 264–296.

219. Danielsion JJ, Perez N, Romano JD, et al. Modelling Toxoplasma gondii infection in a 3D cell culture system in vitro: comparison with infection in 2D cell monolayers. *PLoS One* 2018; 13: e0208558.

220. Harker KS, Ueno N and Lodoen MB. Toxoplasma gondii dissemination: a parasite’s journey through the infected host. *Parasite Immunol* 2015; 37: 141–149.

221. Duan X, Han Y, Yang L, et al. Identification of drugs blocking SARS-CoV-2 infection using human pluripotent stem cell-derived colonial organoids. *bioRxiv* 2020; DOI:10.1101/2020.05.02.073320.

222. Han Y, Yang L, Duan X, et al. Identification of candidate COVID-19 therapeutics using hPSC-derived lung organoids. *bioRxiv* 2020; DOI: 10.1101/2020.05.05.079095.

223. Xia H and Lazartigues E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. *J Neurochem* 2008; 107: 1482–1494.

224. Fiddes IT, Lodewijg GA, Mooring M, et al. Human-specific NOTCH2NL genes affect notch signaling and cortical neurogenesis. *Cell* 2018; 173: 1356–1369.e1322.

225. Ramani A, Muller L, Osternann PN, et al. SARS-CoV-2 targets neurons of 3D human brain organoids. *EMBO J* 2020, DOI: 10.15252/embj.2020106230.

226. Song E, Zhang C, Israelow B, et al. SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. *Cell Stem Cell* 2020. DOI: 10.1016/j.stem.2020.09.016.

227. Jacob F, Pather SR, Huang WK, et al. Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. *Cell Stem Cell* 2020. DOI: 10.1016/j.stem.2020.09.016.

228. Yang L, Han Y, Nilsson-Payant BE, et al. A Human pluripotent stem cell-based platform to Study SARS-CoV-2 tropism and model virus infection in human cells and organoids. *Cell Stem Cell* 2020; 27: 125–136.e127.

229. Zhang BZ, Chu H, Han S, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. *Cell Res* 2020; 30(10): 928–931.

230. Mesci P, Macia A, Saleh A, et al. Sosfosvirer protects human brain organoids against SARS-CoV-2. *bioRxiv* 2020; DOI: 10.1101/2020.05.30.125856.

231. Pellegrini L, Albecka A, Mallery DL, et al. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. *Cell Stem Cell* 2020; 27(6):951–961.e5.
232. Hoffmann M, Kleine-Weber H and Pohlmann S. A multi-basic cleavage site in the spike protein of SARS-CoV-2 Is essential for infection of human lung cells. *Mol Cell* 2020; 78: 779–784.e775.

233. Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 2020; 11: 1620.

234. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci USA* 2020; 117: 7001–7003.

235. Lun MP, Monuki ES and Lehtinen MK. Development and functions of the choroid plexus-cerebrospinal fluid system. *Nat Rev Neurosci* 2015; 16: 445–457.

236. Schwerk C, Tenenbaum T, Kim KS, et al. The choroid plexus-a multi-role player during infectious diseases of the CNS. *Front Cell Neurosci* 2015; 9: 80.

237. Zempel H and Mandelkow E. Lost after translation: mis-sorting of Tau protein and consequences for Alzheimer disease. *Trends Neurosci* 2014; 37: 721–732.

238. Mesci P, Macia A, Moore SM, et al. Blocking Zika virus vertical transmission. *Sci Rep* 2018; 8: 1218.

239. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sci* 2020; 248: 117477.

240. Danta CC. CNS penetration ability: a critical factor for drugs in the treatment of SARS-CoV-2 brain infection. *ACS Chem Neurosci* 2020; 11: 2137–2144.

241. Ormel PR, Vieira de Sa R, van Bodegraven EJ, et al. Microglia innately develop within cerebral organoids. *Nat Commun* 2018; 9: 4167.

242. Sidhaye J and Knoblich JA. Brain organoids: an ensemble of bioassays to investigate human neurodevelopment and disease. *Cell Death Differ*. Epub ahead of print 1 June 2020. DOI: 10.1038/s41418-020-0566-4.